Translate page


Keynote presentations from the recipients of the 2015 iCMLf Prizes

At the 17th Annual John Goldman Conference on CML the iCMLf Directors awarded the Foundation’s prize medals. This was followed by keynote presentations from the three prize winners. You can view web streams of the keynote presentations here as part of the iCMLf Virtual Education Program.

Collage prize winners 2015



  • 2015 Rowley Prize: Professor Richard Van Etten
  • 2015 John Goldman Prize: Professor Michele Baccarani
  • 2015 ERSAP Prize: Pat Garcia-Gonzalez (The MAX Foundation)
Richard van Etten 1




Keynote Rowley Prize 2015:
Mouse models of tyrosine kinase-driven hematologic neoplasms: historical perspectives & new insights 
Professor Richard Van Etten

Chao Family Comprehensive Cancer Center, University of California, Irvin (USA)

  • Elucidation of the Ph chromosome breakpoint
  • An altered ABL protein in a mouse leukemia virus
  • Barriers to retroviral gene expression in stem cells
  • Retroviral BM transduction / transplant model
  • Retroviral mouse models of CML
  • What mouse models have taught us about CML
  • The future of CML mouse model 
Michele Baccarani 1  

Keynote Goldman Prize 2015:

Discussing chronic myeloid leukemia: The known and the unknown
Professor Michele Baccarani

University of Bologna, Italy Institute of Hematology and Medical Oncology 'L. and A. Seràgnoli', S. Orsola University Hospital Bologna, University of Bologna (Italy)

  • Survival of CML by therapy
  • CML in the 21st century
  • CML today
  • Leukocyte alkaline phosphotase
  • Eosinophils and basophils
  • BCR-ABL1 in healthy subjects
  • What causes CML resistance?
  • Perspectives of treatment

Please note:
Due to technical difficulties there is no web stream available of this presentation and you can only see the slides



Pat Garcia Gonzalez 1   

Keynote Inaugural ERSAP Prize 2015:

Chronic myeloid leukemia: Leading the ways to global access to oncology treatment
Pat Garcia-Gonzalez

CEO and co-founder of The MAX Foundation

  • Access to imatinib in low and middle-income countries
  • GIPAP's novel access model
  • Patient assistance tracking system (PATS)
  • Barriers to access to imatinib in low and middle-income countries
  • Access to diagnostics
  • Support and education: decreasing socio-economic barriers
  • Lessons learned and current challenges